Early identification of stimulant treatment responders, partial responders and non-responders using objective measures in children and adolescents with hyperkinetic disorder.

BACKGROUND   The aim of this study was to evaluate stimulant medication response following a single dose of methylphenidate (MPH) in children and young people with hyperkinetic disorder using infrared motion analysis combined with a continuous performance task (QbTest system) as objective measures. The hypothesis was put forward that a moderate testdose of stimulant medication could determine a robust treatment response, partial response and non-response in relation to activity, attention and impulse control measures. METHODS   The study included 44 children and young people between the ages of 7-18 years with a diagnosis of hyperkinetic disorder (F90 & F90.1). A single dose-protocol incorporated the time course effects of both immediate release MPH and extended-release MPH (Concerta XL, Equasym XL) to determine comparable peak efficacy periods post intake. RESULTS   A robust treatment response with objective measures reverting to the population mean was found in 37 participants (84%). Three participants (7%) demonstrated a partial response to MPH and four participants (9%) were determined as non-responders due to deteriorating activity measures together with no improvements in attention and impulse control measures. CONCLUSION   Objective measures provide early into prescribing the opportunity to measure treatment response and monitor adverse reactions to stimulant medication. Most treatment responders demonstrated an effective response to MPH on a moderate testdose facilitating a swift and more optimal titration process.

[1]  Martin H. Teicher,et al.  Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD. , 2004, Journal of child and adolescent psychopharmacology.

[2]  J. Swanson,et al.  Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. , 2004, Journal of child and adolescent psychopharmacology.

[3]  J. Swanson,et al.  A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). , 2004, Pediatrics.

[4]  W. Pelham,et al.  Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. , 2001, Pediatrics.

[5]  Martin H. Teicher,et al.  Rate dependency revisited: understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder. , 2003, Journal of child and adolescent psychopharmacology.

[6]  M. Byrnes,et al.  A clinical protocol for determining methylphenidate dosage levels in ADHD , 1997 .

[7]  Martin H. Teicher,et al.  Objective measurement of hyperactivity and attentional problems in ADHD. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[8]  John Hattie,et al.  A Review of the Research on Interventions for Attention Deficit Hyperactivity Disorder: What Works Best? , 2002 .

[9]  J. Swanson,et al.  National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. , 2004, Pediatrics.

[10]  Martin H. Teicher,et al.  Utility of objective measures of activity and attention in the assessment of therapeutic response to stimulants in children with attention-deficit/hyperactivity disorder. , 2008, Journal of child and adolescent psychopharmacology.

[11]  C. Conners,et al.  Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. , 1999, Pediatric clinics of North America.

[12]  C. Reynolds,et al.  Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. , 2001, The Journal of neuropsychiatry and clinical neurosciences.

[13]  H. DeCory,et al.  Methylphenidate bioavailability from two extended-release formulations. , 2002, International journal of clinical pharmacology and therapeutics.

[14]  D. Coury,et al.  Evaluating Medication Response in ADHD , 1998, Journal of learning disabilities.

[15]  R. Barkley.  The ecological validity of laboratory and analogue assessment methods of ADHD symptoms , 1991, Journal of abnormal child psychology.

[16]  H Meltzer,et al.  Using the Strengths and Difficulties Questionnaire (SDQ) to screen for child psychiatric disorders in a community sample , 2003, International review of psychiatry.

[17]  S. Dalsgaard,et al.  Is OPTAx™ useful for monitoring the effect of stimulants on hyperactivity and inattention? , 2007, European Child & Adolescent Psychiatry.

[18]  M. Kosorok,et al.  Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. , 2001, Pediatrics.

[19]  B. Herpertz-Dahlmann,et al.  Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[20]  J. Hebebrand,et al.  Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate , 2004, European Child & Adolescent Psychiatry.